Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Down Syndrome Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Down Syndrome Overview | 8 | 1 |
| Pipeline Products for Down Syndrome Comparative Analysis | 9 | 1 |
| Down Syndrome Therapeutics under Development by Companies | 10 | 1 |
| Down Syndrome Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Down Syndrome Pipeline Products Glance | 12 | 3 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Down Syndrome Products under Development by Companies | 15 | 1 |
| Down Syndrome Products under Investigation by Universities/Institutes | 16 | 1 |
| Down Syndrome Companies Involved in Therapeutics Development | 17 | 7 |
| AC Immune SA | 17 | 1 |
| Aelis Farma SAS | 18 | 1 |
| Cortice Biosciences, Inc. | 19 | 1 |
| Eisai Co., Ltd. | 20 | 1 |
| F. Hoffmann-La Roche Ltd. | 21 | 1 |
| NeuroNascent, Inc. | 22 | 1 |
| Transition Therapeutics Inc. | 23 | 1 |
| Down Syndrome Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 30 |
| ACI-24 Drug Profile | 33 | 2 |
| ALZ-801 Drug Profile | 35 | 3 |
| APH-1104 Drug Profile | 38 | 1 |
| basmisanil Drug Profile | 39 | 1 |
| D-217 Drug Profile | 40 | 1 |
| donepezil hydrochloride Drug Profile | 41 | 2 |
| Dosmir Drug Profile | 43 | 1 |
| ELND-005 Drug Profile | 44 | 6 |
| minocycline Drug Profile | 50 | 1 |
| NNI-351 Drug Profile | 51 | 1 |
| NNI-362 Drug Profile | 52 | 2 |
| Pentylenetetrazol Drug Profile | 54 | 2 |
| Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome Drug Profile | 56 | 1 |
| Small Molecule to inhibit DYRK1A for CNS Diseases Drug Profile | 57 | 1 |
| Small Molecules for Down Syndrome Drug Profile | 58 | 1 |
| Small Molecules to Inhibit OLIG2 for Down Syndrome Drug Profile | 59 | 1 |
| Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome and Edwards Syndrome Drug Profile | 60 | 1 |
| xamoterol fumarate Drug Profile | 61 | 2 |
| Down Syndrome Discontinued Products | 63 | 1 |
| Down Syndrome Product Development Milestones | 64 | 4 |
| Featured News &Press Releases | 64 | 1 |
| Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome | 64 | 1 |
| Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics | 65 | 1 |
| Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome | 65 | 1 |
| Apr 07, 2014: Transition Therapeutics Announces Development Update | 65 | 2 |
| Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome | 67 | 1 |
| Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome | 67 | 1 |
| Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome | 67 | 1 |
| Appendix | 68 | 2 |
| Methodology | 68 | 1 |
| Coverage | 68 | 1 |
| Secondary Research | 68 | 1 |
| Primary Research | 68 | 1 |
| Expert Panel Validation | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 69 | 1 |